Molecular Breast Imaging Market Projected to Reach USD 1,246.6 Mn by 2030 - Persistence Market Research

The global molecular breast imaging market was valued at US$781.4 million in 2023 and is projected to grow at a CAGR of 6.9%, reaching US$1,246.6 million by 2030. The rising prevalence of breast cancer and advancements in imaging technologies drive market growth. The dual-head gamma camera segment leads due to its superior imaging capabilities. North America dominates the market, owing to advanced healthcare infrastructure, while East Asia is the fastest-growing region due to increasing cancer prevalence and healthcare modernization.

Molecular breast imaging (MBI) is an advanced diagnostic technique designed specifically for breast cancer detection. Unlike traditional mammography, MBI utilizes a radioactive tracer that highlights cellular activity within breast tissue. A gamma camera then captures images to reveal functional and metabolic details, making this method particularly effective for women with dense breast tissue.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33944

Key Highlights from the Report

The global molecular breast imaging market is projected to grow at a 6.9% CAGR from 2023 to 2030.

Increasing breast cancer prevalence is a key growth driver for the market.

The dual-head gamma camera segment dominates due to high imaging sensitivity and accuracy.

North America leads the market, benefiting from strong healthcare infrastructure.

East Asia is experiencing the fastest growth, driven by healthcare modernization.

Technological advancements, including AI integration in MBI, are shaping market trends.

Market Segmentation

By Modality: Single vs. Dual Head Gamma Camera

The dual-head gamma camera segment dominates the market due to its higher sensitivity and better diagnostic accuracy. This modality captures images from multiple angles simultaneously, making it the preferred choice for breast cancer screening, especially in patients with dense breast tissue. On the other hand, the single-head gamma camera segment is expanding due to technological advancements and affordability, attracting healthcare providers looking for cost-effective solutions.

By Imaging Technique: Planar Imaging vs. SPECT Imaging

SPECT imaging is the dominant technique, offering superior 3D imaging capabilities and higher diagnostic accuracy. It enables healthcare professionals to assess spatial distribution, making it essential for comprehensive breast cancer diagnosis. Planar imaging is growing steadily, driven by its cost-effectiveness and ease of integration into existing healthcare infrastructures.

By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes

Hospitals hold the largest market share, given their well-established infrastructure and high patient volume.

Diagnostic imaging centers are expanding rapidly, driven by increasing accessibility and specialized imaging services.

Research institutes are investing in MBI to explore its potential beyond breast cancer detection, including applications in other cancers and metabolic diseases.

Regional Insights

North America: Market Leader

North America leads the molecular breast imaging market due to a well-established healthcare system, high R&D investments, and strong adoption of advanced medical technologies. Regular breast cancer screening programs and government initiatives further boost market growth in this region.

East Asia: Fastest-Growing Market

East Asia is experiencing rapid adoption of MBI technologies, driven by healthcare modernization, rising cancer prevalence, and increasing awareness about early detection. Countries like China, Japan, and South Korea are investing significantly in breast cancer diagnostics, propelling market expansion.

Market Dynamics

Market Drivers

Technological Advancements: Innovations in imaging technology, such as AI-assisted diagnostics and enhanced gamma cameras, are improving diagnostic accuracy.

Rising Breast Cancer Incidence: The increasing prevalence of breast cancer globally is driving demand for early detection technologies.

Growing Awareness & Screening Programs: Government initiatives promoting breast cancer screening are increasing the adoption of MBI.

Personalized Medicine Trends: The shift toward precision medicine is enhancing the demand for highly accurate diagnostic tools like MBI.

Market Restraints

Regulatory Hurdles: Strict regulations on radioactive tracers slow down product approvals and market expansion.

High Cost of MBI Systems: The initial purchase and operational costs limit accessibility, particularly in low-income regions.

Radiation Exposure Concerns: Patient and physician concerns about radiation exposure impact adoption rates.

Market Opportunities

Expanding Applications Beyond Breast Cancer: Research is exploring the potential of MBI in diagnosing other cancers and conditions.

AI Integration in Imaging: AI-powered MBI systems can improve accuracy and efficiency, enhancing early detection outcomes.

Strategic Collaborations: Partnerships between medical imaging firms and research institutions can accelerate innovation.

Emerging Markets: Expanding healthcare infrastructure in developing regions presents new growth opportunities for market players.

Reasons to Buy the Report

✔ Comprehensive market analysis covering growth trends and future projections.
✔ Detailed segmentation insights by modality, imaging technique, application, and end user.
✔ In-depth regional analysis highlighting key markets and emerging opportunities.
✔ Strategic insights on market drivers, restraints, and opportunities.
✔ Competitive landscape overview with key players and recent developments.
✔ Analysis of the impact of AI and digital transformation in medical imaging.

Company Insights

Key Players in the Market

GE Healthcare

Siemens Healthineers

Dilon Technologies, Inc.

Gamma Medica, Inc.

SmartBreast Corporation

CMR Naviscan Corporation

Carestream Health, Inc.

Recent Market Developments

Philips launched the Zenition 10 image-guided therapy system in March 2023, enhancing imaging precision in orthopedic and trauma surgeries.

SmartBreast Corporation acquired Discovery NM750b MBI assets from GE Healthcare in February 2021, strengthening its foothold in breast cancer diagnostics.

Siemens Healthineers introduced AI-powered MBI solutions in 2024, enhancing efficiency and accuracy in breast cancer diagnosis.

Conclusion

The molecular breast imaging market is poised for significant growth, driven by technological advancements, rising breast cancer incidence, and increasing adoption of AI-assisted imaging. While regulatory challenges and high costs remain hurdles, expanding applications and strategic partnerships present lucrative opportunities. With North America leading and East Asia emerging as a key growth hub, the market outlook remains highly promising in the coming years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.